Exacerbations, treatment patterns, utilization, and costs before and after initiating of benralizumab for the treatment of severe eosinophilic asthma

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2022. Available from: www.ginasthma.org; https://ginasthma.org/gina-reports/.
   Google Scholar
• Song P, Adeloye D, Salim H, Dos Santos JP, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of asthma in 2019: a systematic analysis and modelling study. J Glob Health. 2022;12:04052. doi:10.7189/jogh.12.04052.
   PubMed Web of Science ®Google Scholar
• Pate CA, Zahran HS, Qin X, Johnson C, Hummelman E, Malilay J. Asthma surveillance – United States, 2006–2018. MMWR Surveill Summ. 2021;70(5):1–32. doi:10.15585/mmwr.ss7005a1.
   PubMed Web of Science ®Google Scholar
• Levy ML, Bacharier LB, Bateman E, Boulet L-P, Brightling C, Buhl R, Brusselle G, Cruz AA, Drazen JM, Duijts L, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med. 2023;33(1):7. doi:10.1038/s41533-023-00330-1.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Gandhi H, Gilbert I, Murphy KR, Chupp GL. Mapping geographic variability of severe uncontrolled asthma in the United States: management implications. Ann Allergy Asthma Immunol. 2022;128(1):78–88. doi:10.1016/j.anai.2021.09.025.
   PubMed Web of Science ®Google Scholar
• Domingo C, Sicras-Mainar A, Sicras-Navarro A, Sogo A, Mirapeix RM, Engroba C. Prevalence, T2-biomarkers and cost of severe asthma in the era of biologics: the BRAVO-1 study. J Investig Allergol Clin Immunol (online ahead of print on November 22, 2022).
   PubMedGoogle Scholar
• Hansen S, von Bülow A, Sandin P, Ernstsson O, Janson C, Lehtimäki L, Kankaanranta H, Ulrik C, Aarli BB, Fues Wahl H, et al. Prevalence and management of severe asthma in the Nordic countries: findings from the NORDSTAR cohort. ERJ Open Res. 2023;9(2):00687–2022. doi:10.1183/23120541.00687-2022.
   PubMedGoogle Scholar
• Hardtstock F, Krieger J, Wilke T, Lukas M, Ultsch B, Welte R, Quinzler R, Maywald U, Timmermann H. Epidemiology, treatment and health care resource use of patients with severe asthma in Germany – a retrospective claims data analysis. J Asthma. 2023;60:1280–1289.
   PubMed Web of Science ®Google Scholar
• Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi:10.1016/j.jaci.2014.08.042.
   PubMed Web of Science ®Google Scholar
• Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, Busby J, Jackson DJ, Pfeffer PE, Rhee CK, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry. Chest. 2020;157(4):790–804. doi:10.1016/j.chest.2019.10.053.
   PubMed Web of Science ®Google Scholar
• Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, Quirce S, Virchow JC, Holgate S, Expert group of the European Consensus Meeting for Severe Eosinophilic Asthma Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49(5):1700634. doi:10.1183/13993003.00634-2017.
   PubMed Web of Science ®Google Scholar
• Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, Christoff GC, Cosio BG, FitzGerald JM, Heffler E, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021;160(3):814–830. doi:10.1016/j.chest.2021.04.013.
   PubMed Web of Science ®Google Scholar
• Pavlidis S, Takahashi K, Ng Kee Kwong F, Xie J, Hoda U, Sun K, Elyasigomari V, Agapow P, Loza M, Baribaud F, et al. “T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Eur Respir J. 2019;53(1):1800938. doi:10.1183/13993003.00938-2018.
   PubMed Web of Science ®Google Scholar
• Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJM, Bel EH, Sterk PJ. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115–120. doi:10.1136/thoraxjnl-2014-205634.
   PubMed Web of Science ®Google Scholar
• Hiles SA, Gibson PG, McDonald VM. Disease burden of eosinophilic airway disease: comparing severe asthma, COPD and asthma-COPD overlap. Respirology. 2021;26(1):52–61. doi:10.1111/resp.13841.
   PubMed Web of Science ®Google Scholar
• Davila Gonzalez I, Moreno Benitez F, Quirce S. Benralizumab: a new approach for the treatment of severe eosinophilic asthma. J Investig Allergol Clin Immunol. 2019;29(2):84–93. doi:10.18176/jiaci.0385.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Marks GB, Baraket M, et al. Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. ERJ Open Res. 2019;5(4):00056–2019. doi:10.1183/23120541.00056-2019.
   PubMedGoogle Scholar
• Food and Drug Administration. Fasenra (benralizumab) injection, for subcutaneous use. 2017. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf. [last accessed May 2, 2023].
   Google Scholar
• Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9(9):CD010834. doi:10.1002/14651858.CD010834.pub3.
   PubMed Web of Science ®Google Scholar
• Chung Y, Katial R, Mu F, Cook EE, Young J, Yang D, Betts KA, Carstens DD. Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study. Ann Allergy Asthma Immunol. 2022;128(6):669–676.e6. doi:10.1016/j.anai.2022.02.017.
   PubMed Web of Science ®Google Scholar
• Carstens D, Maselli DJ, Mu F, Cook EE, Yang D, Young JA, Betts KA, Genofre E, Chung Y. et al. Largest real-world effectiveness study of benralizumab for severe eosinophilic asthma: ZEPHYR 2. J. Allergy Clin. Immunol. Pract. 2023;11(7):2150–2161.e4.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel J-M, Sundararajan V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq433.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow AN, McBrien C, Unni B, Porsbjerg CM, Al-Ahmad M, Ambrose CS, Dahl Assing K, von Bülow A, Busby J, Cosio BG, et al. Real World biologic use and switch patterns in severe asthma: data from the International Severe Asthma Registry and the US CHRONICLE Study. J Asthma Allergy. 2022;15:63–78. doi:10.2147/JAA.S328653.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2023. Available from: www.ginasthma.org; https://ginasthma.org/gina-reports/.
   Google Scholar